These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22730859)

  • 41. Alternative methods for anticoagulation monitoring in pediatric patients with applicability to a patient with severe hemophilia A and circulating inhibitor.
    McNamara JL; Lombardi JP; Ferguson R; Manning PB; Gruppo RA
    J Extra Corpor Technol; 2001 Dec; 33(4):239-42. PubMed ID: 11806436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of Point-of-Care ACT Coagulometers and Anti-Xa Activity During Cardiopulmonary Bypass.
    Falter F; MacDonald S; Matthews C; Kemna E; Cañameres J; Besser M
    J Cardiothorac Vasc Anesth; 2020 Nov; 34(11):2921-2927. PubMed ID: 32620484
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel thrombelastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during cardiopulmonary bypass.
    Chavez JJ; Foley DE; Snider CC; Howell JC; Cohen E; Muenchen RA; Carroll RC
    Anesth Analg; 2004 Nov; 99(5):1290-1294. PubMed ID: 15502019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Percutaneous transluminal coronary angioplasty: comparison of arterial vs. venous activated clotting time.
    Pesola GR; Johnson A; Pesola DA
    Cathet Cardiovasc Diagn; 1996 Feb; 37(2):140-4. PubMed ID: 8808068
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass.
    Welsby IJ; McDonnell E; El-Moalem H; Stafford-Smith M; Toffaletti JG
    J Clin Monit Comput; 2002 Jul; 17(5):287-92. PubMed ID: 12546261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Standardized Bolus of 5 000 IU of Heparin Does not Lead to Adequate Heparinization during Non-cardiac Arterial Procedures.
    Doganer O; Jongkind V; Blankensteijn JD; Yeung KK; Wiersema AM
    Ann Vasc Surg; 2021 Feb; 71():280-287. PubMed ID: 32768536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting Heparin Responsiveness in Children Before Cardiopulmonary Bypass: A Retrospective Cohort Study.
    Nakamura S; Honjo O; Crawford-Lean L; Foreman C; Sano M; O'Leary JD
    Anesth Analg; 2018 May; 126(5):1617-1623. PubMed ID: 29309315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
    Maul TM; Wolff EL; Kuch BA; Rosendorff A; Morell VO; Wearden PD
    Pediatr Crit Care Med; 2012 Nov; 13(6):e363-71. PubMed ID: 22940857
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Validation of a new whole blood coagulation monitoring system.
    Jaryno S; Bennett K; Loder C; Zucker ML; Pan CM; LaDuca FM
    J Extra Corpor Technol; 2002 Dec; 34(4):271-5. PubMed ID: 12533064
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of different anticoagulant agents on fibrinopeptide a generation.
    Tobu M; Iqbal O; Messmore HL; Ma Q; Hoppensteadt DA; Fareed J
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):273-92. PubMed ID: 14653437
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty.
    Helft G; Choktron S; Beygui F; Le Feuvre C; Elalamy I; Metzger JP; Vacheron A; Samama MM
    Cathet Cardiovasc Diagn; 1998 Nov; 45(3):329-31. PubMed ID: 9829899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hand-held personal digital assistant program for the HEMOCHRON RxDx heparin and protamine dosing system.
    El Rouby S; Rinehart K; Zucker ML; LaDuca FM
    J Extra Corpor Technol; 2003 Sep; 35(3):212-7. PubMed ID: 14653423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activated clotting time (ACT) testing: analysis of reproducibility.
    Zucker ML; Jobes C; Siegel M; Jobes D; LaDuca FM
    J Extra Corpor Technol; 1999 Sep; 31(3):130-4. PubMed ID: 10847955
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test.
    Wallock M; Jeske WP; Bakhos M; Walenga JM
    Perfusion; 2001 Mar; 16(2):147-53. PubMed ID: 11334198
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
    Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
    J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bedside testing with the new CoaguChek Pro activated clotting time assay in dialysis.
    Bommer J; Schwab M
    Artif Organs; 2002 Apr; 26(4):387-90. PubMed ID: 11952512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial.
    Dillinger JG; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Nicolau JC; Henry P; Kedev S; Wiviott SD; Sabatine MS; Mehta SR; Steg PG
    Circ Cardiovasc Interv; 2018 Jun; 11(6):e006084. PubMed ID: 29895599
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An evaluation of two activated clotting time monitors during cardiac surgery.
    Reich DL; Zahl K; Perucho MH; Thys DM
    J Clin Monit; 1992 Jan; 8(1):33-6. PubMed ID: 1538250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
    Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
    Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new device for in vitro evaluation of thrombogenicity.
    Lermusiaux P; How TV; Black RA
    Med Eng Phys; 2006 May; 28(4):389-93. PubMed ID: 16185909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.